ORMP To Meet With FDA, Second Time's No Charm For OCUL, Panel Backs PFE

Today's Daily Dose brings you news about Clearside Biomedical's phase II TYBEE trial; Ocular's huge disappointment for second time on its product candidate DEXTENZA; Oramed's upcoming end-of-phase II meeting with the FDA for oral insulin capsule; FDA panel recommendation of Pfizer's MYLOTARG and Sanofi's acquisition of privately-held Protein Sciences.

from RTT - Biotech http://ift.tt/2ucv46f
via IFTTT